Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.54 Analyst target: $6.40 Upside: 151.97%
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.